# Ascendis Pharma (ASND) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ASND
## Company Profile
- Ticker: ASND
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Denmark
## Stock Data
- Close: 255.46 USD
- Market cap: 13381493850 USD
- Last updated: 2026-08-12
## Business Overview
### TransCon Technology
Ascendis Pharma applies its TransCon prodrug platform to create long-acting therapies that release an unmodified parent drug over time. Its portfolio spans endocrinology, rare growth disorders and oncology.
### Commercial Endocrinology Portfolio
YORVIPATH is a parathyroid-hormone replacement therapy for chronic hypoparathyroidism. SKYTROFA is a once-weekly growth-hormone therapy, and YUVIWEL is approved in the United States for children with achondroplasia.
### Growth-Disorder Development
Ascendis is studying TransCon CNP in infants with achondroplasia and in hypochondroplasia. It is also evaluating TransCon CNP combined with TransCon hGH to address growth and skeletal complications.
### Oncology Program
Onvapegleukin alfa is a long-acting IL-2 beta/gamma agonist in Phase 1/2 development, including combination treatment for platinum-resistant ovarian cancer.
## Why The Stock Is Moving

The latest monitored company update is “Ascendis Pharma Reports Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- European regulatory decision for YUVIWEL in the fourth quarter of 2026.
- Initiation of a Phase 3 TransCon CNP study in hypochondroplasia in the second half of 2026.
- Initiation of a Phase 3 TransCon CNP plus TransCon hGH study in pediatric achondroplasia in the fourth quarter of 2026.

## Recent News
- 2026-08-13 11:30 EST — [Ascendis Pharma Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ASND/ascendis-pharma-reports-second-quarter-2026-financial-results-a256f90a) — Source: Ascendis Pharma
- 2026-08-06 20:01 EST — [Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026](https://biopharmsignal.com/news/ASND/ascendis-to-report-second-quarter-2026-financial-results-and-provide-business-up-f021ee6b) — Source: Ascendis Pharma
- 2026-08-06 12:00 EST — [Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.](https://biopharmsignal.com/news/ASND/ascendis-announces-coach-week-78-results-and-provides-update-on-achondroplasia-p-13eabecd) — Source: Ascendis Pharma
- 2026-06-30 12:30 EST — [Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial](https://biopharmsignal.com/news/ASND/children-with-achondroplasia-treated-with-transcon-cnp-showed-continued-improvem-93d02f62) — Source: Ascendis Pharma
- 2026-06-26 20:01 EST — [Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®](https://biopharmsignal.com/news/ASND/ascendis-joins-multiple-russell-u-s-indexes-including-the-russell-3000-russell-1-d1ad8aa7) — Source: Ascendis Pharma